Yan Leyfman: Curative Strategies and Precision Medicine in Sickle Cell Disease
Yan Leyfman, Medical Oncologist, Co-Founder and Executive Director of MedNews Week, Medical Correspondent at OncLive, shared on LinkedIn about a recent article he and his colleagues co-authored, published in Encyclopedia, adding:
“For decades, a cure for sickle cell disease (SCD) depended on finding the right donor for an allogeneic stem cell transplant – a life-saving option that remained out of reach for many patients and carried the lifelong risk of graft-versus-host disease (GVHD).
Today, that paradigm is changing.
The emergence of autologous gene therapies, including Lyfgenia and Casgevy, has ushered in a new era of precision medicine, offering curative potential without the need for a donor or the risk of GVHD.
At the same time, advances in transplantation continue to expand access and improve outcomes, making treatment decisions more complex – and more exciting – than ever before.
In our new review, we explore:
- How stem cell transplantation has evolved over the past several decades
- The science and clinical data behind gene-editing and gene-addition therapies
- The strengths and limitations of each curative strategy
- The remaining barriers to affordability, accessibility, and global implementation
As curative therapies move from promise to clinical reality, understanding where the field stands – and where it’s headed – is essential for clinicians, researchers, and patients alike.”
Title: The New Era of Curative Therapies for Sickle Cell Disease: A Comprehensive Review of Allogeneic Transplantation and Autologous Gene Therapy
Authors: Ahmed Hashim Azeez, Sreesha Phani Durga Rithika Kodamanchili, Vraj JigarKumar Rangrej, Harshitha Vallabhaneni, Yan Leyfman, Adhith Theyver, Taha Kassim Dohadwala, Chandler Park

Stay updated with Hemostasis Today.
-
Nov 16, 2026, 15:35Jim Hoffman: Could Blood Purification Change the Fight Against Cancer?
-
Nov 16, 2026, 15:16How Do Artificial Hearts Affect Platelet Function? – Platelets Journal
-
Nov 16, 2026, 15:10Assessing Coagulation Activation in DOAC – Treated Patients – JTH
-
Nov 16, 2026, 15:00Davide Antonio Mei: Should Anticoagulation Continue After AF Ablation?
-
Nov 16, 2026, 14:55Danielle Boyle: Beyond Platelet Counts – Why Patient Stories Matter
-
Nov 16, 2026, 14:28Jan Sloves: The Future of Vascular Ultrasound
-
Nov 16, 2026, 13:49Bahman Rasouli: A Rare Vascular Manifestation of Recurrent Papillary Thyroid Carcinoma
-
Nov 16, 2026, 13:28Muhammad Danyal: Platelet Patterns in Hepatitis B and C
-
Nov 16, 2026, 12:52Frank Nocken: Alzheimer’s Research Expands Beyond Amyloid-Based Treatments